Low-molecular-weight heparin and cancer survival: Review of the literature and pooled analysis of 1,726 patients treated for at least three months

Pathophysiology of Haemostasis and Thrombosis

Volumn 33, Issue 4, 2003, Pages 197-201

  Conti, Serenella ^a   Guercini, Francesco ^a   Iorio, Alfonso ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Cancer survival; Heparin, low molecular weight; Unfractionated heparin; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

BLEEDING; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HUMAN; LONG TERM CARE; META ANALYSIS; PRIORITY JOURNAL; REVIEW;

HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SURVIVAL RATE; TIME; VENOUS THROMBOSIS;

EID: 10844249206     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081508     Document Type: Review

References (21)

1. Agostino D, Grossi CE, Cliffton EE: Effect of heparin on circulating Walker carcinoma 256 cells. J Natl Cancer Inst 1961; 27: 17-24.
2. Zacharsky L, Ornstein D: Heparin and cancer. Thromb Haemost 1998; 80: 10-23.
3. Folkman J, Langer R, Linhardt RJ, et al: Inhibition of angiogenesis and tumour regression caused by heparin or heparin fragments in the presence of cortisone. Science 1983; 221: 719-725.
4. Green D, Hull RD, Brant R, Pineo GF: Lower mortality in cancer patients treated with low molecular weight versus standard heparin. Lancet 1992; 339: 1497.
5. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg J: Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996; 100: 268-277.
6. Gould MK, Dembitzer MD, Doyle RL, Hastie TJ, Garber AM: Low molecular weight heparin compared with unfractionated heparin for the treatment of acute deep venous thrombosis. Ann Intern Med 1999; 130: 800-809.
7. Hettiarachchi RJK, Smorenburg SM, Ginsberg J, Levine M, Prins MK, Buller HR: Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999; 82: 947-952.
8. Collins R, Gay R, Godwin J, Peto R: Avoidance of large biases and large random errors in the assessment of treatment effects: The need of systematic overviews. Stat Med 1987; 6/3: 245-254.
9. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
10. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, et al: Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-197.
11. Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV: Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomised trial. World J Surg 1996; 20: 521-526.
12. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, et al: Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999; 30: 283-290.
13. Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, et al: Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999; 81: 26-31.
14. Veiga F, Escriba A, Maluenda MP, et al: Low-molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocumarol) in the long-term treatment of deep venous thrombosis in the elderly: A randomised trial. Thromb Haemost 2000; 84: 559-564.
15. Lopez-Beret P, Orgaz A, Fontcuberta J, et al: Low-molecular weight heparin versus oral anticoagulant in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001; 33: 77-90.
16. Meyer G, Marjanovic Z, Valcke J, et al: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 2002; 162: 1729-1735.
17. Lee A, Levine M, Beker R, et al: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349/2: 146-153.
18. Hull R, Pineo G, Mah A, Brant R: The Lite Investigators. Long-term low molecular weight heparin treatment versus anticoagulant therapy for proximal deep vein thrombosis. Blood 2000; 96: 1933 (abstract).
19. Hamann H: Sekundärprophylaxe nach tiefer Venenthrombose. Niedermolekulares Heparin versus Coumarin. Zentralbl Chir 1999; 124:24-26.
20. Kakkar VV: Dalteparin prevention of recurrent DVT - A study vs. warfarin. Haemostasis 1994; 24: 45.
21. Kakkar AK, Levine MN, Kadziola Z, et al: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer. The Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.